{
  "trial_id": "NCT01234766",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Previously untreated, histologically confirmed follicular lymphoma classification",
      "label": "unknown"
    },
    {
      "criterion": "grade 1, 2 or 3a",
      "label": "unknown"
    },
    {
      "criterion": "Ann Arbor stages of II to IV with either symptomatic or bulky disease (>5 cm); or disease progression",
      "label": "met"
    },
    {
      "criterion": "18 years of age or older",
      "label": "met"
    },
    {
      "criterion": "ECOG PS <2",
      "label": "unknown"
    },
    {
      "criterion": "Normal organ and marrow function defined as below: Absolute neutrophil count (ANC) >= 1,000/mm3 Platelet count >=100,000/mm3 Patients with ANC less than 1,000/mm3 and/or platelets below 100,000/mm3 are still eligible for study entry as long as there is >50% bone marrow involvement with lymphoma",
      "label": "unknown"
    },
    {
      "criterion": "Adequate hepatic function",
      "label": "unknown"
    },
    {
      "criterion": "Adequate renal function",
      "label": "unknown"
    },
    {
      "criterion": "Measureable disease with at least one lesion measuring > 2cm in its greatest transverse diameter",
      "label": "met"
    },
    {
      "criterion": "Female subjects of childbearing potential must have a negative pregnancy test (urine or serum b-HCG) at screening and within 1 week prior to the start of treatment with Y-90 ibritumomab tiuxetan",
      "label": "unknown"
    },
    {
      "criterion": "Voluntary written informed consent must be given before performance of any study-related procedure",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Prior chemotherapy, immunotherapy, or monoclonal antibody therapy",
      "label": "triggers"
    },
    {
      "criterion": "Receiving any other investigational agents",
      "label": "triggers"
    },
    {
      "criterion": "Primary CNS lymphoma",
      "label": "unknown"
    },
    {
      "criterion": "Known HIV",
      "label": "unknown"
    },
    {
      "criterion": "Treatment with therapeutic doses of systemic steroids within 4 weeks of beginning study treatment (cycle 1, day -7); topical use of corticosteroids and systemic replacement of corticosteroids for adrenal insufficiency are allowed",
      "label": "does_not_trigger"
    },
    {
      "criterion": "Malignant pleural, pericardial or peritoneal effusions",
      "label": "triggers"
    },
    {
      "criterion": "Known history of myelodysplastic syndrome (MDS) or found to have MDS",
      "label": "unknown"
    }
  ],
  "notes": "Patient has a large pericardial effusion with Burkitt's lymphoma, but no CNS involvement. Has a history of viral encephalitis/meningitis and CSF leak, which may be relevant for study eligibility.",
  "_meta": {
    "topic_id": "4",
    "trial_id": "NCT01234766",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}